AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.780

+0.0405.41%

Volume:289.66K

Turnover:219.17K

Market Cap:192.73M

PE:-28.43

High:0.780

Open:0.740

Low:0.725

Close:0.740

52wk High:1.435

52wk Low:0.225

Shares:247.09M

Float Shares:102.11M

Volume Ratio:1.51

T/O Rate:0.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.027

EPS(LYR):-0.027

ROE:-99.95%

ROA:-53.59%

PB:20.20

PE(LYR):-28.43

Loading ...

Overview Company News Filings

ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap

Simply Wall St.

Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%

MT Newswires Live

Nyrada Inc-Preliminary Final Report

THOMSON REUTERS

Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive

MT Newswires Live

Several Insiders Invested In Nyrada Flagging Positive News

Simply Wall St.

Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate

MT Newswires Live

Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion

MT Newswires Live

Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate

MT Newswires Live

Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation

Simply Wall St.

Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%

MT Newswires Live

Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%

MT Newswires Live

Nyrada Inc-Xolatryp Enhances Anthracycline Anti-Tumour Efficacy

THOMSON REUTERS

BRIEF-Nyrada Seeks Trading Halt

Nyrada Inc - Trading Halt Pending Announcement on Pre-Clinical Oncology Study

THOMSON REUTERS

Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage

MT Newswires Live

Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/NYR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.78,"timestamp":1787638320000,"preClose":0.74,"halted":0,"volume":289663,"delay":0,"changeRate":0.054054054054054106,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":247092830,"eps":-0.02744,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"08-25 16:12:00 AEST","open":0.74,"high":0.78,"low":0.725,"amount":219173,"amplitude":0.074324,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.02744,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.74,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":1.509290329618443,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NYR.AU","preClose":0.78,"auctionPrice":0.8,"auctionVolume":25032,"auctionTime":1787693401071,"referenceTime":1787653803093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787693401071}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-53.59%","roe":"-99.95%","lyrEps":-0.02744,"volumeRatio":1.509290329618443,"shares":247092830,"dividePrice":0,"high":0.78,"amplitude":0.074324,"preClose":0.74,"low":0.725,"week52Low":0.225,"pbRate":"20.20","psRate":"95.82","week52High":1.435,"institutionHeld":0,"latestPrice":0.78,"eps":-0.02744,"divideRate":0,"volume":289663,"delay":0,"ttmEps":-0.02744,"open":0.74,"prevYearClose":1.12,"prevWeekClose":0.745,"prevMonthClose":0.64,"prevQuarterClose":0.45,"fiveDayClose":0.72,"twentyDayClose":0.52,"sixtyDayClose":0.485},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662508557","title":"ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2662508557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662508557?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:02","pubTimestamp":1787684525,"startTime":"0","endTime":"0","summary":"The ASX is poised for a strong start today, buoyed by positive corporate reporting and lower oil prices, even as global markets face mixed signals. For investors interested in exploring beyond the major players, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite their somewhat outdated name, these stocks can present valuable growth potential when backed by solid financial fundamentals.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NYR.AU","BK7088","ALC.AU","BK7094","AL3.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661558592","title":"Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661558592","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661558592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:54","pubTimestamp":1787273690,"startTime":"0","endTime":"0","summary":"Nyrada  said its Xolatryp drug candidate provided significant protection to cardiac function against progressive doxorubicin-induced cardiotoxicity in a preclinical study, according to a Friday filing with the Australian bourse.Doxorubicin is an anthracycline drug widely used as a first-line treatment for both solid and metastatic tumors, and is considered a \"backbone drug\" in oncology, the company said.Doxorubicin treatment weakened the heart's ability to pump and empty blood effectively, and Xolatryp delivered benefits across four key measures of heart performance that were negatively impacted by doxorubicin, Nyrada said.The magnitude of functional protection was comparable to dexrazoxane, which is the only approved cardioprotective agent, per the filing.Nyrada said it will assess the design and feasibility of a potential phase 1b clinical trial of Xolatryp in the oncology setting.The company's share gained 5% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845604","title":"Nyrada Inc-Preliminary Final Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845604?lang=en_us&edition=fundamental","pubTime":"2026-08-18 11:05","pubTimestamp":1787022349,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUE6NYCPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654096125","title":"Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2654096125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654096125?lang=en_us&edition=fundamental","pubTime":"2026-07-27 11:23","pubTimestamp":1785122584,"startTime":"0","endTime":"0","summary":"Nyrada  ended the June quarter with a cash balance of about AU$8.4 million, up from AU$6.7 million as of March 31, according to a Monday filing with the Australian bourse.Cash operating outflows for the June quarter totaled about AU$1.7 million, offset by AU$60,000 of interest income and the receipt of a roughly AU$2.5 million research and development tax incentive from the Australian government, per the filing.The company said its phase 2a clinical trial of Xolatryp in heart attack patients remains on track for completion next year, with the final patient expected to be dosed in mid-2027.Nyrada shares fell 1% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652961266","title":"Several Insiders Invested In Nyrada Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2652961266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652961266?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:01","pubTimestamp":1784498465,"startTime":"0","endTime":"0","summary":"Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/several-insiders-invested-in-nyrada-flagging-positive-news","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/several-insiders-invested-in-nyrada-flagging-positive-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649058614","title":"Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2649058614","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649058614?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:03","pubTimestamp":1783299790,"startTime":"0","endTime":"0","summary":"Nyrada  has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.The company's shares fell 2% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738679","title":"Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738679","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738679?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:53","pubTimestamp":1781578431,"startTime":"0","endTime":"0","summary":"Nyrada  said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640973230","title":"Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640973230","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640973230?lang=en_us&edition=fundamental","pubTime":"2026-06-03 12:24","pubTimestamp":1780460646,"startTime":"0","endTime":"0","summary":"Nyrada  completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.The company's shares fell 6% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638650682","title":"Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638650682","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638650682?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:59","pubTimestamp":1779944362,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/heres-why-were-not-too-worried-about-nyradas-asxnyr-cash-bur","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/heres-why-were-not-too-worried-about-nyradas-asxnyr-cash-bur","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637051158","title":"Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051158","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637051158?lang=en_us&edition=fundamental","pubTime":"2026-05-21 11:32","pubTimestamp":1779334377,"startTime":"0","endTime":"0","summary":"Nyrada  said a total of about 7 million unlisted options are due to expire on June 29, including 2.9 million with an exercise price of AU$0.40, 2 million at AU$0.60, and 2 million at AU$0.90, according to a Thursday Australian bourse filing.The company's shares fell 3% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894073","title":"Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636894073?lang=en_us&edition=fundamental","pubTime":"2026-05-20 11:17","pubTimestamp":1779247066,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) said that a rodent study demonstrated that its xolatryp drug candidate exhibits anti-tumor activity both as a monotherapy and in combination with doxorubicin, a first-line chemotherap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636898833","title":"Nyrada Inc-Xolatryp Enhances Anthracycline Anti-Tumour Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636898833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636898833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 07:13","pubTimestamp":1779232439,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUE5F9DST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838375","title":"BRIEF-Nyrada Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636838375?lang=en_us&edition=fundamental","pubTime":"2026-05-19 14:54","pubTimestamp":1779173689,"startTime":"0","endTime":"0","summary":"BRIEF-Nyrada Seeks Trading Halt May 19 (Reuters) - Nyrada NYR.AX:TRADING HALT PENDING ANNOUNCEMENT ON PRE-CLINICAL ONCOLOGY STUDYFurther company coverage: NYR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41V1IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838398","title":"Nyrada Inc - Trading Halt Pending Announcement on Pre-Clinical Oncology Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636838398?lang=en_us&edition=fundamental","pubTime":"2026-05-19 14:54","pubTimestamp":1779173667,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41V1IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629109579","title":"Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage","url":"https://stock-news.laohu8.com/highlight/detail?id=2629109579","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629109579?lang=en_us&edition=fundamental","pubTime":"2026-04-22 11:52","pubTimestamp":1776829926,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) confirmed that the Nepean Hospital in New South Wales was activated as the first site in its Protect-MI phase 2a clinical trial assessing Xolatryp in potentially reducing myocardial i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620299589","title":"Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299589","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620299589?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:12","pubTimestamp":1773879136,"startTime":"0","endTime":"0","summary":"Nyrada  said it was on track to begin site initiation visits for its PROTECT-MI Phase IIa trial, which is designed to assess the safety and preliminary efficacy of its drug candidate Xolatryp in addressing myocardial ischemia reperfusion injury in patients suffering a STEMI heart attack, inMarch, according to a Thursday Australian bourse filing.Seven hospitals were selected as initial sites, with the first patient dosing expected in April. The enrolment of patients in the PROTECT-MI study will finish once 100 evaluable patients are dosed.Its shares fell 2% in recent trading on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}